For pMHC, which has a low density on the cell surface (e.g., for NY-ESO-1157–165/HLA-A*02:01, 10–50 copies per cell [19]), a monovalent molecule with a high affinity is more effective in enriching molecules on the tumor cell side than a bivalent molecule with a low affinity, which requires a mature screening platform to obtain a specific clone with a high affinity. Here, HLA-A is linked to neoplasm.